Lukas Andreas Heger

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Axel Bauer, Michael Schreinlechner, Nikolay Sappler et al. · The Lancet Respiratory Medicine · 2021 · 101 citations · Full text

Open-label Trial, Hypertension, Cardiovascular Disease +9

Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients

Samuel D. Robinson, Marie Follo, David Haenel et al. · Acta Pharmacologica Sinica · 2017 · 27 citations · Full text

Heart Failure, Engineering, Cardiovascular Disease +11

Neutrophil NLRP3 promotes cardiac injury following acute myocardial infarction through IL-1β production, VWF release and NET deposition in the myocardium

Lukas Andreas Heger, Nicolas Schommer, Stijn Van Bruggen et al. · Scientific Reports · 2024 · 20 citations · Full text

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

Dawid L. Staudacher, Vera Putz, Lukas Andreas Heger et al. · European Heart Journal Acute Cardiovascular Care · 2017 · 18 citations · Full text

Inflammation in acute coronary syndrome: Expression of TLR2 mRNA is increased in platelets of patients with ACS

Lukas Andreas Heger, Marcus Hortmann, Madlin Albrecht et al. · PLoS ONE · 2019 · 15 citations · Full text